Table 1.
The clinicopathological features of PLC patients.
| Total | Low FIB | Normal FIB | High FIB | p | |
|---|---|---|---|---|---|
| FIB (g/L) | 2.80 ± 1.03 | 1.70 ± 0.22 | 2.71 ± 0.53 | 5.14 ± 0.99 | <0.001 |
| Age | 1029 | 163 | 762 | 104 | 0.084 |
| ≤50 | 338(32.8) | 62(38.0) | 244(32.0) | 32(30.8) | |
| >50 | 691(67.0) | 101(62.0) | 518(68.0) | 72(69.2) | |
| Sex | 0.001 | ||||
| Female | 254(24.6) | 22(13.5) | 200(26.2) | 32(30.8) | |
| Male | 775(75.1) | 141(86.5) | 562(73.8) | 72(69.2) | |
| BMI | 23.27 ± 3.10 | 23.13 ± 2.87 | 23.36 ± 3.09 | 22.86 ± 3.47 | 0.261 |
| ALT (U/L) | 41.67 ± 39.03 | 39.94 ± 26.63 | 40.38 ± 38.65 | 53.86 ± 53.74 | 0.003 |
| AST (U/L) | 38.36 ± 32.17 | 34.66 ± 24.48 | 37.01 ± 28.76 | 53.99 ± 54.69 | <0.001 |
| AFP | 0.989 | ||||
| ≤400 | 817(79.2) | 129(79.1) | 605(79.6) | 83(79.8) | |
| >400 | 210(20.3) | 34(20.9) | 155(20.4) | 21(20.2) | |
| ASA score | 0.046 | ||||
| ≤2 | 990(95.9) | 155(95.1) | 739(97.0) | 96(92.3) | |
| >2 | 39(3.8) | 8(4.9) | 23(3.0) | 8(7.7) | |
| Child-Pugh grade | 0.002 | ||||
| A | 1019(99.0) | 160(98.2) | 759(99.6) | 100(96.2) | |
| B | 10(1.0) | 3(1.8) | 3(0.4) | 4(3.8) | |
| ECOG performance status | 0.002 | ||||
| 0 | 951(92.2) | 12(7.4) | 49(6.4) | 17(16.3) | |
| 1–2 | 78(7.6) | 151(92.6) | 713(93.6) | 87(83.7) | |
| Tumor differentiation | 0.255 | ||||
| Ⅰ | 18(1.7) | 3(1.8) | 13(1.7) | 2(1.9) | |
| Ⅱ | 689(66.8) | 114(69.9) | 515(67.6) | 60(57.7) | |
| Ⅲ | 312(30.2) | 43(26.4) | 229(30.1) | 40(38.5) | |
| Ⅳ | 10(1.0) | 3(1.8) | 5(0.7) | 2(1.9) | |
| TNM stage | 1029 | 163 | 762 | 104 | <0.001 |
| Ⅰ | 370(35.9) | 93(57.1) | 263(34.5) | 14(13.5) | |
| Ⅱ | 384(37.2) | 37(22.7) | 293(38.5) | 54(51.9) | |
| Ⅲ | 241(23.4) | 32(19.6) | 185(24.3) | 24(23.1) | |
| Ⅳ | 34(3.3) | 1(0.6) | 21(2.8) | 12(11.5) | |
| HBsAg (+) | 699(67.7) | 131(80.4) | 511(67.1) | 57(54.8) | <0.001 |
| Anti-HCV (+) | 18(1.7) | 3(1.8) | 14(1.8) | 1(1.0) | 0.811 |
| Tumor size | <0.001 | ||||
| ≤5 cm | 687(66.6) | 140(85.9) | 515(67.6) | 32(30.8) | |
| >5 cm | 342(33.1) | 23(14.1) | 247(32.4) | 72(69.2) | |
| Tumor number | 0.209 | ||||
| Solitary | 834(80.8) | 137(84.0) | 608(79.8) | 89(85.6) | |
| Multiple | 195(18.9) | 26(16.0) | 154(20.2) | 15(14.4) | |
| Tumor resection range | <0.001 | ||||
| ≤3 segments | 762(73.8) | 143(87.7) | 566(74.3) | 53(51.0) | |
| >3 segments | 267(25.9) | 20(12.3) | 196(25.7) | 51(49.0) | |
| Cirrhosis (+) | 659(63.9) | 131(80.4) | 476(62.5) | 52(50.0) | <0.001 |
| Portal hypertension (+) | 101(9.8) | 15(9.2) | 66(8.7) | 20(19.2) | 0.003 |
| Vascular invasion (+) | 120(11.6) | 14(8.6) | 85(11.2) | 21(20.2) | 0.011 |
| Satellite focus (+) | 179(17.3) | 20(12.3) | 129(16.9) | 30(28.8) | 0.002 |
| Hepatic portal occlusion (+) | 423(41.0) | 58(35.6) | 315(41.3) | 50(48.1) | 0.125 |
| Intraoperative blood loss (mL) | 390.16 ± 421.39 | 406.38 ± 438.73 | 363.99 ± 387.79 | 556.44 ± 570.19 | <0.001 |
| Preoperative PT (s) | 11.85 ± 3.63 | 12.47 ± 2.36 | 11.55 ± 1.00 | 13.11 ± 10.63 | <0.001 |
| Preoperative APTT (s) | 28.57 ± 10.54 | 30.73 ± 6.59 | 27.53 ± 3.93 | 32.88 ± 29.87 | <0.001 |
| Preoperative Hb (g/L) | 137.42 ± 20.29 | 136.74 ± 23.39 | 138.97 ± 19.17 | 127.16 ± 20.23 | <0.001 |
| Preoperative PLT ( × 109/L) | 169.14 ± 93.10 | 117.55 ± 55.52 | 167.76 ± 84.39 | 260.04 ± 128.25 | <0.001 |
| Preoperative ALB(g/L) | 41.47 ± 4.73 | 41.27 ± 5.16 | 41.94 ± 4.34 | 38.39 ± 5.62 | <0.001 |
| Preoperative GLB(g/L) | 30.01 ± 5.55 | 28.15 ± 5.63 | 29.72 ± 5.00 | 35.01 ± 6.46 | <0.001 |
| Hospital-stay days | 14.67 ± 6.50 | 14.43 ± 6.81 | 14.59 ± 6.47 | 15.69 ± 6.20 | 0.232 |
| OS(%) | 571(55.3) | 96(82.1) | 435(75.3) | 40(54.1) | <0.001 |